Get the Stockscreener App
17.64
6.77%
-1.28
Pre-market:
17.25
-0.39
-2.21%
Caredx Inc stock is traded at $17.64, with a volume of 741.41K.
It is down -6.77% in the last 24 hours and down -28.99% over the past month.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
See More
Previous Close:
$18.92
Open:
$18.78
24h Volume:
741.41K
Relative Volume:
0.91
Market Cap:
$977.71M
Revenue:
$312.78M
Net Income/Loss:
$-143.56M
P/E Ratio:
-6.5576
EPS:
-2.69
Net Cash Flow:
$1.22M
1W Performance:
-6.67%
1M Performance:
-28.99%
6M Performance:
-38.90%
1Y Performance:
+67.52%
1-Day Range:
$17.52
$18.96
1-Week Range:
$17.52
$19.16
52-Week Range:
$7.42
$34.84
Caredx Inc Stock (CDNA) Company Profile
Name
Caredx Inc
Sector
Industry
Phone
415-287-2300
Address
8000 MARINA BLVD, BRISBANE, CA
Compare CDNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDNA
Caredx Inc
|
17.64 | 977.71M | 312.78M | -143.56M | 1.22M | -2.69 |
|
TMO
Thermo Fisher Scientific Inc
|
508.90 | 191.99B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
204.09 | 145.87B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
117.33 | 33.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
406.29 | 33.04B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
181.43 | 31.99B | 15.41B | 1.37B | 2.11B | 7.50 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-15-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-28-24 | Initiated | Wells Fargo | Underweight |
| Aug-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| May-13-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-09-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Aug-15-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-11-23 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-07-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-03-23 | Downgrade | Craig Hallum | Buy → Hold |
| Mar-03-23 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Jul-20-21 | Resumed | BTIG Research | Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-26-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-30-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-08-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-02-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-26-20 | Initiated | BTIG Research | Buy |
| Jun-19-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| May-09-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-15-19 | Initiated | Jefferies | Buy |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Neutral |
| Nov-27-17 | Initiated | H.C. Wainwright | Buy |
| Jun-14-16 | Reiterated | Mizuho | Buy |
| Sep-29-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-25-15 | Initiated | Craig Hallum | Buy |
| Mar-18-15 | Reiterated | Mizuho | Buy |
View All
Caredx Inc Stock (CDNA) Latest News
CareDx, Inc (NASDAQ:CDNA) Shares Bought by US Bancorp DE - Defense World
CareDx: Some Litigation Clouds Have Cleared - Seeking Alpha
CareDx director George Bickerstaff sells $367,102 in common stock - Investing.com India
CareDx Director Makes Significant Stock Sale! - TipRanks
CareDx director George Bickerstaff sells $367,102 in common stock By Investing.com - Investing.com UK
Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem - Simply Wall St
CareDx Launches Two Expanded Indications for AlloSure Testing Services - BioSpace
Major Breakthrough: CareDx AlloSure Now Covers Infant Heart and Dual-Organ Transplant Testing - StockTitan
Principal Financial Group Inc. Has $406,000 Stock Position in CareDx, Inc (NASDAQ:CDNA) - Defense World
Statutory Earnings May Not Be The Best Way To Understand CareDx's (NASDAQ:CDNA) True Position - Yahoo Finance
HC Wainwright Has Negative Estimate for CareDx Q1 Earnings - Defense World
(CDNA) On The My Stocks Page - Stock Traders Daily
Rhumbline Advisers Boosts Stake in CareDx, Inc (NASDAQ:CDNA) - Defense World
New York State Common Retirement Fund Sells 15,584 Shares of CareDx, Inc (NASDAQ:CDNA) - Defense World
CareDx (NASDAQ:CDNA) Trading Down 7.9% Following Analyst Downgrade - Defense World
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc.CDNA - Business Wire
CareDx stock price target cut to $25 at H.C. Wainwright By Investing.com - Investing.com Canada
CareDx (NASDAQ:CDNA) Price Target Cut to $25.00 by Analysts at HC Wainwright - Defense World
CareDx stock price target cut to $25 at H.C. Wainwright - Investing.com
Where CareDx Stands With Analysts - Benzinga
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc.CDNA - ACCESS Newswire
CareDx, Inc (NASDAQ:CDNA) Shares Sold by ARK Investment Management LLC - MarketBeat
CareDx (NASDAQ:CDNA) Shares Gap Up Following Strong Earnings - Defense World
Decoding CareDx Inc (CDNA): A Strategic SWOT Insight - GuruFocus.com
CareDx (NASDAQ:CDNA) Upgraded by StockNews.com to "Buy" Rating - MarketBeat
CareDx, Inc (NASDAQ:CDNA) Q4 2024 Earnings Call Transcript - MSN
Bradley & Co. Private Wealth Management LLC Invests $269,000 in CareDx, Inc (NASDAQ:CDNA) - MarketBeat
CareDx (NASDAQ:CDNA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Stephens Reaffirms Overweight Rating for CareDx (NASDAQ:CDNA) - MarketBeat
CareDx, Inc. SEC 10-K Report - TradingView
CareDx Inc. Reports Strong Growth and Positive Outlook - TipRanks
CareDx (NASDAQ:CDNA) Issues Quarterly Earnings Results - MarketBeat
CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN
CareDx: Q4 Earnings Snapshot - mySA
CareDx Inc (CDNA) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Caredx Inc earnings beat by $0.41, revenue topped estimates - Investing.com South Africa
CareDx Announces Fourth Quarter and Full Year 2024 Financial Results - BioSpace
CareDx Reports Strong 2024 Financial Performance - TipRanks
Earnings call transcript: CareDx Q4 2024 beats EPS forecast, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: CareDx Q4 2024 beats EPS forecast, stock rises - Investing.com
CareDx Reports Strong 2024 Financial Results and Growth - TipRanks
Earnings Flash (CDNA) CAREDX INC. Reports Q4 Revenue $86.6M, vs. FactSet Est of $84.1M - Marketscreener.com
Report: Developing Opportunities within VEREIT, CareDx, CymaBay Therapeutics, and HarscoFuture Expectations, Projections Moving into 2019 - ACCESS Newswire
CareDx gets $96M jury verdict overturned in Natera patent dispute - MSN
CareDx stock down despite court win over Natera (CDNA:NASDAQ) - Seeking Alpha
CareDx Inc (CDNA) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Court invalidates patents claimed against CareDx By Investing.com - Investing.com Australia
CareDx Escapes $96 Million Verdict Over Natera DNA-Test Patents - Bloomberg Law
Caredx Inc Stock (CDNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):